GH Research Raises $125 Million to Fund DMT Treatment for Depression
GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
The first conference of its kind, the Jewish Psychedelic Summit, will explore the connection between psychedelics and Judaism.
Toronto’s Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.
Former NHL player Daniel Carcillo’s psychedelic startup Wesana Health is preparing to take the company public.
Adults with depression who were abused or neglected as children…
Atai Life Sciences is working to combine psychedelics with brain-computer interfaces for mental health treatment.
This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.
The Heroic Dose conference will explore the use of psychedelic therapies to treat post-traumatic stress disorder, substance abuse, and suicide among military veterans and first responders.
Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.
Psilocybin is showing relief as treatment for cluster headaches — a painful condition that affects more than 300,000 Americans a year.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.